Zaphir v Health Ombudsman [2017] QCAT 193

Decision date: 16 June 2017
“PROFESSIONS AND TRADES – HEALTH CARE PROFESSIONALS – HEALTH PRACTITIONERS REGULATION NATIONAL LAW GENERALLY – where the practitioner was an unregistered health practitioner – where the Health Ombudsman took immediate action by issuing an interim prohibition order in relation to the practitioner under s 68 of the Health Ombudsman Act 2013 (Qld) – where the interim prohibition order prohibited the practitioner from any employment (paid or otherwise) in a clinical or non-clinical capacity which relates to the provision of any health service – whether the Tribunal believes the action is necessary to protect public health or safety.”
Find decision here.

Dorris Maharaj v Northern Health [2017] FWC 2997

Decision date: 20 June 2017
“Application for relief from unfair dismissal – dismissal harsh, unjust or unreasonable – applicant unfairly dismissed – remedy – reinstatement sought – satisfied could return to position occupied prior to dismissal – no conditions placed on reinstatement – ancillary matters considered – reinstatement ordered.”
Find decision here.

Seven Network Limited v South Eastern Sydney Local Health District [2017] NSWCATAD 210

Decision date: 27 June 2017
“Government Information (Public Access) – application for disclosure of CCTV footage of assaults on staff at hospitals – whether overriding public interest against disclosure – disclosure of personal information and health information – disclosure prejudicing the effective exercise of the agency’s functions – whether pixelation of faces and identifying marks would avoid concerns – impact on operations of hospitals if footage recording treatment of patients was released.”
Find decision here.

Direct-to-Consumer Medical Testing in the Era of Value-Based Care

JAMA. 2017; 317(24): 2485-2486.
Author: Kimberly Lovett Rockwell
“This Viewpoint documents the growing market share of direct-to-consumer (DTC) medical testing despite growing recognition that it represents low-value or harmful care and proposes policy options to increase accountability and protect patients from adverse consequences of DTC testing.”
Find article here.

A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia

BMJ Open 2017; 7: e016701.
Authors: Fabbri A, Grundy Q, Mintzes B, et al
“To analyse patterns and characteristics of pharmaceutical industry sponsorship of events for Australian health professionals and to understand the implications of recent changes in transparency provisions that no longer require reporting of payments for food and beverages.”
Find article here.

The case for an Indigenous Bioethics

Global Bioethics Blog, 25 June 2017
Author: Stuart Rennie
“Indigenous communities in the Americas experience a disproportionate incidence of illness and disease compared to the general population. They also possess sophisticated ethical traditions which diverge and not infrequently conflict with Western-oriented bioethics. This culture gap between patient, provider and ethicist is no small public health concern—it can foster feelings of alienation and distrust which compromise the relationship between those in need of care and those able to offer it. Research ethicists have already made considerable efforts to bring sensitivity for aboriginal cultural mores into their discipline, but bioethicists have been slower out of the gate.”
Find article here.

Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement

JAMA. 2017; 317(24): 2479-2480.
Authors: Sham Mailankody, Vinay Prasad
“This Viewpoint uses the recent instance of disease awareness promotion on a television soap opera to discuss questions about the role and regulation of novel forms of direct-to-consumer disease awareness marketing.”
Find article here.